AstraZeneca's Kid Asthma Drug Patent Invalid, Judge Says

Law360, New York (April 2, 2013, 2:27 PM EDT) -- A New Jersey federal judge on Monday shot down AstraZeneca PLC's bid to block four generic drugmakers from producing no-name versions of the pharmaceutical giant's pediatric asthma medication, and declared one of the company's patents invalid.

U.S. District Judge Renee Marie Bumb entered judgment in favor of Apotex Inc., Breath Ltd., Actavis Inc. and Sandoz Inc., rejecting allegations that their planned generic versions of Pulmicort Respules would infringe two AstraZeneca's patents.

The judge said U.S. Patent No. 6,598,603 was invalid as obvious and anticipated and that...
To view the full article, register now.